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Abstract
Osteoarthritis (OA) is increasingly prevalent worldwide and is
associated with a significant economic burden. Despite the
increasing number of patients with OA, treatments to manage the
condition remain symptomatic, designed to control pain, and
improve function and quality of life while limiting adverse events.
Both the EULAR (European League Against Rheumatism) and the
OARSI (Osteoarthritis Research Society International) issued new
guidelines in 2007 and 2008 recommending a combination of
nonpharmacological and pharmacological modalities to manage
OA effectively. Because of gastrointestinal risks (including ulcer
complications) and cardiovascular risks (including hypertension
and thrombotic events associated with nonsteroidal anti-inflam-
matory drugs [NSAIDs]), these guidelines propose acetaminophen
as the first choice anti-inflammatory agents. However, NSAIDs are
considered to be more effective than acetaminophen for relief of
pain. Given the efficacy, safety, and tolerability issues associated
with NSAIDs, development of new agents to manage the pain
associated with arthritis but without the cardiovascular and
gastrointestinal adverse events remains a priority. This review
considers current recommendations for the treatment of OA, the
most recent evidence on the cardiovascular risks associated with
current NSAID treatments, and the potential of newer anti-
inflammatory agents with improved benefit-risk profiles.
Introduction
Osteoarthritis (OA) is becoming increasingly prevalent world-
wide because of the combination of an aging population and
growing levels of obesity. A study reported in 2005 [1]
indicated that OA affected 9.6% of men and 18% of women
aged 60 years or older, or a total of 26 million individuals.
Although age is the strongest predictor of the development of
OA, obesity, trauma, and physically demanding occupations
and activities also increase the risk for OA of the hand, knee,
and hip [2,3]. Because the most powerful predictor of OA
development and progression is increasing age, it is expected
that more individuals will develop the disease, making it even
more essential that effective strategies to manage the pain
and disability associated with OA are developed. Along with
the current armamentarium of available therapies, develop-
ment of new agents with potentially improved safety profiles
may offer new alternatives for these patients.
Burden of osteoarthritis
Functional burden
OA imposes a significant functional burden on affected indivi-
duals. NHANES III (the Third National Health and Nutrition
Examination Study) revealed that more than 8% of US adults
have symptomatic hand OA, and there were no sex-specific
differences [4]. Furthermore, these individuals had difficulty
lifting 10 pounds, dressing and eating, and had significantly
increased use of analgesics, particularly acetaminophen.
There was no increase in the use of nonsteroidal anti-
inflammatory drugs (NSAIDs). A French study [5] found that
more than 80% of clinical OA patients reported limitations in
their daily lives, including basic tasks, work and leisure
activities, and these limitations affected patients who were
retired as well as those still working. Finally, Heuts and co-
workers [6] measured the association between pain-related
fear and daily living in patients with OA and found that pain
levels and fear of (re)injury were both associated with
significant functional limitations. Interestingly, radiological
findings were not significant predictors as compared with
pain-related fear, emphasizing the need for effective
analgesics that can be used in the long term.
Economic burden
OA imposes a significant economic burden for both patients
and health-care systems. Rabenda and colleagues [7]
measured the direct and indirect costs to individuals with OA.
The mean direct cost to patients was €44.5 per patient-
month, and this included hospitalizations, drugs, and
physician examinations. In addition, patients also required a
mean 0.8 days sick leave per patient-month, resulting in sub-
stantial costs to employers, whereas unaffected care givers
required an average 0.2 days sick leave per patient-month. A
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study conducted in the USA [8] revealed that patients with
OA incur direct costs of more than $2,600 per year, approxi-
mately twice as much as do individuals without OA. Similarly,
a Canadian study [9] confirmed that 60% of patients
experienced costs directly related to their OA and that much
of this was due to time lost from work and leisure activities for
patients and unpaid care givers.
Health care systems also bear an economic burden due to
OA. A study [10] calculated that from July 1993 to June
1994, the annual cost to an individual health maintenance
organization for 10,101 patients with OA was more than $4.7
million, including hospital care, medications, and ambulatory
care. The authors pointed out that the OA care was
infrequent and that the largest portion of the expenditure was
for hospitalizations, which affected only 5% of the OA
patients; this indicates that there is a need for improved OA
management. A French study [11] calculated that in 2002 the
direct costs of OA in France were €1.6 billion, which
comprised about 1.7% of expenditure for the French health
care system. Expenditures in 2002 were 156% higher than in
1993, primarily due to an increased number of patients.
These numbers also reinforce the need for effective
strategies to manage the symptoms of OA and decrease the
number of patients with functional disability.
Treatment recommendations
Summary of guidelines
As the number of individuals with OA increases, effective
strategies to manage the pain and disability of OA will
become even more important. Guidelines for the manage-
ment of OA have been published recently by both the Osteo-
Arthritis Research Society International (OARSI) [12,13] and
the European League Against Rheumatism (EULAR) [14-16].
Experts from multiple disciplines, who analyzed and weighed
the scientific and clinical evidence as well as previous
guidelines, developed recommendations for the management
of knee, hip, and hand OA. The guidelines indicate that a
combination of pharmacological and nonpharmacological
modalities is the most effective strategy to manage the pain
and disability associated with OA.
Pharmacological guidelines for the management of OA
recommend acetaminophen up to 4 g/day as first-line therapy
and suggest that alternative pharmacological therapy should
be used only in the presence of an inadequate response and
severe pain [13-15]. This is because of a perceived lower risk
for adverse events from acetaminophen as compared with
NSAIDs. Both OARSI and EULAR guidelines recommend a
switch to NSAIDs if acetaminophen cannot adequately
control symptoms or if there are signs of clinical inflammation
(Table 1) [13]. Once the decision has been made to use
NSAIDs, OARSI and EULAR guidelines both recommend the
lowest effective dose and, in patients with increased
gastrointestinal risk, consideration of a gastroprotective agent
such as proton pump inhibitors or misoprostol. All of the
guidelines recommend monitoring of individual patients after
initiation of NSAID treatment. Finally, the OARSI and EULAR
guidelines recommend that if patients do not respond to oral
analgesics, then they should receive intra-articular injections
of either corticosteroids or hyaluronate for OA of the knee or
hip, followed by the use of opioids and narcotics only when
all other pharmacological options have been considered.
Surgery, including joint replacement, is recommended only as
a last resort.
Despite the recommendation that acetaminophen be used as
first-line therapy, there is evidence that NSAIDs may be more
effective than acetaminophen for the control of pain in
patients with OA. Several published studies have suggested
that acetaminophen is not as effective as either NSAIDs
[17,18] or placebo [19]. In addition, a systematic review
conducted by the US Agency for Healthcare Research and
Quality [20] indicated that although there does not appear to
be efficacy differences between selective and nonselective
NSAIDs, all NSAIDs appear to be superior to both aceta-
minophen and placebo for the treatment of OA symptoms.
Although the recent EULAR and OARSI guidelines recognize
differences in efficacy, the recommendations for initial
treatment with acetaminophen remain based on issues of
safety [13-15].
American Heart Association recommendations for the
use of nonsteroidal anti-inflammatory drugs
The American Heart Association (AHA) recently issued a
controversial statement that included a stepped care
approach to the management of musculoskeletal symptoms
[21]. The AHA recommends that for patients with symptoms
that cannot be controlled by nonpharmacological approaches,
acetaminophen, full doses of aspirin, nonacetylated
salicylates, or short-term narcotics should be used as initial
therapy, and only those individuals who cannot tolerate the
previous treatments or who require long-term or high-dose
therapy should receive NSAIDs. Nonselective NSAIDs should
be used first, and only if symptoms are not controlled should
NSAIDs with ‘increasing degrees of COX-2 [cyclo-
oxygenase-2] inhibitory activity’ be used before ‘ultimately
concluding with the COX-2 selective NSAIDs.’ The AHA
rationale for this approach is that some COX-2 selective
NSAIDs might carry increased risk for cardiovascular events
compared with nonselective NSAIDs.
Concerns about the AHA recommendations were addressed
in an editorial published in 2007 [22]. First, Moskowitz and
coworkers [22] wrote that nonacetylated salicylates tend to
be less effective than NSAIDs and may take longer to benefit
patients. There is also no evidence to support the contention
that nonacetylated salicylates have an improved cardio-
vascular safety profile compared with NSAIDs. In addition,
the authors of the editorial stated that full-dose aspirin
confers increased risk for gastrointestinal bleeding as well as
the potential for increased hemorrhagic stroke. The authorsPage 3 of 7
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suggested that the AHA reconsider their recommendations.
Finally, because there is no clinical support for the idea that it
is possible to differentiate cardiovascular risk among selec-
tive and nonselective NSAIDs on the basis of in vitro COX-2/
COX-1 inhibition ratios, the editorial suggested that COX-2
selective agents should be considered, particularly in patients
with increased gastrointestinal risk, although NSAID drugs
should only be prescribed after evaluation of the risk/benefit
balance for the individual patient [22].
Moskowitz and coworkers [22] also disagreed with the AHA
regarding the early use of opioids to treat patients with
musculoskeletal pain, arguing that long-term use is not
recommended by either the American Pain Society or the
American Academy of Pain Management. In addition, the
editorial points out that patients with OA tend to be older and
therefore more likely to experience adverse events associated
with opioid use; these include dizziness, confusion, and risk
for falling, which could in turn increase the risk for hip fracture.
Benefit/risk profile of nonselective and
cyclo-oxygenase-2 inhibiting nonsteroidal
anti-inflammatory drugs
Cardiovascular risk
A number of studies have been conducted to determine the
cardiovascular risks associated with both selective and
nonselective NSAIDs. An epidemiological study conducted
by McGettigan and Henry [23] identified increased risk for
cardiovascular events with rofecoxib, whereas Hernandez-
Diaz and colleagues [24] observed increased risk with
rofecoxib and diclofenac, and presented data suggesting an
increase in risk for cardiovascular events with ibuprofen. In
their meta-analysis, Kearney and coworkers [25] reported
that the COX-2 selective NSAIDs rofecoxib and celecoxib, as
well as high doses of the nonselective NSAIDs ibuprofen and
diclofenac, were all associated with moderately increased risk
for cardiovascular events. In contrast, high-dose naproxen
was not associated with increased vascular risk. The authors
went on to state that there was insufficient data to determine
whether naproxen is protective, as has been suggested in
other studies.
Although the meta-analysis reported by Kearney and
coworkers was unable to determine whether cardiovascular
risk differed between aspirin users and nonusers, Strand [26]
discussed epidemiological studies reporting that concomitant
aspirin therapy decreases the risk for cardiovascular events
with COX-2 inhibitors as well as some nonselective NSAIDs,
but not with ibuprofen [27,28]. That investigator also
indicated that these events were confirmed in the CLASS
(Celecoxib Long-term Arthritis Safety Study) [29] and
TARGET (Therapeutic Arthritis Research and Gastrointestinal
Event Trial) [30] trials.
In addition to an increase in the risk for cardiovascular events,
NSAIDs increase blood pressure. Two meta-analyses [31,32]
concluded that NSAIDs increase both systolic and diastolic
blood pressures, and a later clinical trial [33] indicated that
although treatment with rofecoxib significantly elevated 24-
hour systolic blood pressure, this was not the case in patients
receiving celecoxib or naproxen. However, the authors noted
that all three NSAIDs destabilized hypertension control,
reiterating the need for careful monitoring of patients with
hypertension.
Gastrointestinal risks
NSAIDs are also associated with gastrointestinal events,
including dyspepsia and heartburn (which affect up to 60%
of NSAID users), as well as gastric and duodenal ulcers [34].
Garcia Rodriguez and Hernandez-Diaz [35] found that the
risk for symptomatic but uncomplicated peptic ulcer
increased from 1.03 per 1,000 person-years in individuals
who did not use NSAIDs or aspirin to 4.0 per 1,000 person-
years for nonaspirin NSAID users. In addition, this risk
increased slightly when patients used NSAIDs for more than
6 months. Furthermore, the use of aspirin either with or
Available online http://arthritis-research.com/supplements/10/S2/S1
Table 1
OARSI pharmacological recommendations for the management of knee and/or hip OA
Strength of recommendation
Recommendation (%) (95% CI)
Acetaminophen (up to 4 g/day) can be an effective initial oral analgesic for the treatment of mild to  92 (88-99)
moderate pain in patients with knee or hip OA. In the absence of an adequate response, or in the presence 
of severe pain and/or inflammation, alternative pharmacologic therapy should be considered based on relative 
efficacy and safety, as well as concomitant medications and co-morbidities.
In patients with symptomatic hip or knee OA, NSAIDs should be used at the lowest effective dose but their  93 (88-99)
long-term use should be avoided if possible. In patients with increased gastrointestinal risk, either a COX-2 
selective agent or a nonselective NSAID with co-prescription of a PPI or misoprostol for gastroprotection may 
be considered, but NSAIDs, including both nonselective and COX-2 selective agents, should be used with 
caution in patients with cardiovascular risk factors.
Reprinted from Zhang et al. [13] with permission from Elsevier. COX, cyclo-oxygenase; NSAID, nonsteroidal anti-inflammatory drug; OA,
osteoarthritis; OARSI, Osteoarthritis Research Society International; PPI, proton pump inhibitor.without other NSAIDs increased the risk for uncomplicated
peptic ulcer. A systematic review of epidemiological studies
[36] showed that the pooled relative risk for a complicated
peptic ulcer was 3.8 for nonselective NSAID use, although
the review did find some differences between specific
NSAIDs. An observational study of elderly patients conduc-
ted to determine the risk for complicated gastrointestinal
events in patients receiving NSAIDs [37] found that the
incidence of complicated upper gastrointestinal bleeding with
nonselective NSAIDs was 4.0, whereas the risk among those
using celecoxib was 1.0. This illustrates that COX-2 selective
inhibitors do decrease the risk for gastrointestinal complica-
tions.
A decreased risk for gastrointestinal events has also been
observed in clinical trials. For example, the CLASS study [29]
revealed that celecoxib users had fewer symptomatic ulcers
and complications than did individuals who received
therapeutic doses of nonselective NSAIDs, although the
statistical significance was not reached at 1 year. In addition,
the MEDAL (Multinational Etoricoxib and Diclofenac Arthritis
Long-term) [38] study demonstrated that individuals who
received etoricoxib had significantly fewer uncomplicated
gastrointestinal events than those who received diclofenac.
Patient risk factors that increase the risk for developing
gastrointestinal side effects include age, a history of ulcer or
dyspepsia,  Helicobacter pylori status, and concurrent
diseases (for review [39]).
The question of whether low-dose aspirin abrogates the
gastrointestinal protection of COX-2 inhibitors is continuing
to be addressed. Strand [26] argued that although evidence
from the CLASS and TARGET studies does not show a
significant benefit, the MEDAL study identified significantly
fewer complicated ulcer events with etoricoxib and aspirin
than with diclofenac and aspirin.
Balancing cardiovascular and gastrointestinal risks of
nonsteroidal anti-inflammatory drugs
Moore and coworkers [40] calculated the absolute risk for
cardiovascular and gastrointestinal events and determined that
although gastrointestinal complications occur more frequently
with nonselective NSAIDs than with selective COX-2 inhibitors,
serious cardiovascular events occur at approximately equal
rates. A retrospective cohort study examining administrative
data from elderly patients who filled a prescription for NSAIDs
or acetaminophen [41] showed that among patients who did
not use aspirin, the risk for hospitalization for acute myocardial
infarction/gastrointestinal bleeding was greater with naproxen,
but the risk associated with celecoxib was comparable to that
with acetaminophen. In aspirin users, both naproxen and
celecoxib appeared to be the least toxic. Based on these data,
Jones and colleagues [39] developed evidence-based recom-
mendations according to the gastrointestinal risks and the
cardiovascular risks at the individual level (Table 2).
Renal risks
Renal adverse events associated with NSAID use include
decreased renal perfusion, edema, increased blood pressure,
and interstitial nephritis [42,43]. Although these events are
relatively rare, the number of patients receiving NSAIDs
makes the risks clinically relevant, and patients at increased
risk include those with age-related declines in glomerular
filtration rate, those with hypovolemia, and those with
congestive heart failure, cirrhosis, or nephrosis (for review
[44]). Based on the adverse events associated with
rofecoxib, it is possible that adverse events are attributable to
a class effect. However, a meta-analysis performed to
quantify the risks for renal events (including renal dysfunction,
hypertension, and peripheral edema) associated with COX-2
inhibitors [45] found that although rofecoxib was associated
with increased renal events, no increase was seen with other
COX-2 selective NSAIDs.
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Table 2
Clinicians guide to anti-inflammatory therapy
No or low gastrointestinal risk NSAID gastrointestinal risk
No cardiovascular risk  Nonselective NSAID (cost consideration) COX-2 selective inhibitor
(without aspirin) or
Nonselective NSAID + PPI
or
COX-2 selective inhibitor + PPI for patients with previous 
gastrointestinal bleeding
Cardiovascular riska Naproxenb Add PPI irrespective of NSAID
(with aspirin) Addition of PPI if gastrointestinal risk of  COX-2 selective inhibitor + PPI for those with previous 
aspirin/NSAID combination warrants  gastrointestinal bleeding
gastroprotection
aContraindications to nonselective nonsteroidal anti-inflammatory drugs (NSAIDs) include heart failure and treatment of perioperative pain in the
setting of coronary artery bypass surgery. Contraindications for selective cyclo-oxygenase (COX)-2 inhibitors include established ischemic heart
disease, cereberovascular disease, peripheral arterial disease, and treatment of perioperative pain within the setting of coronary artery bypass
surgery. bNonselective or selective (low-dose) NSAID without established aspiring interaction if naproxen is ineffective. Data from Jones and
coworkers [39]. PPI, proton pump inhibitor.Acetaminophen risks
Despite published recommendations stating that acetamino-
phen has a better safety profile than NSAIDs [13,15], recent
reports have suggested that there are more adverse events
associated with acetaminophen than was previously believed.
For example, a UK nested case-control analysis including
more than 950,000 individuals between 1993 and 1998 [46]
showed that individuals who used more than 2 g/day
acetaminophen had a relative risk of 3.6 for upper gastro-
intestinal complications versus relative risks of 2.4 and 4.9 for
low/medium and high doses of NSAIDs, respectively. These
findings were supported by other studies. One [47] found
that among patients aged 65 years or older, those receiving
higher doses of acetaminophen had an increased risk for
gastrointestinal events compared with those receiving lower
doses. Another [48] revealed that use of a combination of a
nonselective NSAID plus acetaminophen may increase the
risk compared with either agent alone. In addition, there are
studies in the literature that suggest that acetaminophen use
may be associated with a modest increase in risk for renal
functional decline in women consuming more than 3 g/day
[49] and that in patients with early-stage chronic renal failure
acetaminophen use may exacerbate the effects of renal
failure [50]. Furthermore, studies suggest that acetamino-
phen use is associated with a moderate increase in risk for
incident hypertension in both men [51] and women [52].
Given these results, clinicians must consider the safest
therapeutic agent for individual patients with OA.
The cyclo-oxygenase inhibiting nitric oxide
donating class
Given the safety issues described above, there is a clear
need to develop drugs that have the efficacy of NSAIDs but
with an improved safety profile. Cyclo-oxygenase-inhibiting
nitric oxide donating drugs (CINODs) may offer one
alternative, and the potential ability of CINODs to ameliorate
gastric damage due to NSAIDs is illustrated in Figure 1 [53].
These drugs are synthesized by linking a nitric oxide moiety to
an NSAID via an ester linkage. They have been shown in
laboratory and early clinical studies to be efficacious in the
treatment of pain and inflammation, and they may help to
reduce NSAID-induced gastric damage [2,54-56]. Naproxci-
nod was shown to induce significantly less gastric damage
than the parent compound naproxen, while exhibiting equiva-
lent analgesic and anti-inflammatory activities in an animal
model [57]. Furthermore, clinical studies have demonstrated
a trend toward lower blood pressure in patients receiving
naproxcinod as compared with naproxen [58]. More research
will help to determine whether CINODs are effective agents
for the treatment of OA.
Conclusion
Based on the current recommendations, paracetamol/
acetaminophen should be the first line drug to be prescribed
because of a safer profile compared with NSAIDS, even if its
efficacy is not as clear on an evidence-based medicine
approach.  NSAIDS are the second line, although many
adverse events may occur, some of them potentially serious.
So, the objectives now are to find new ways to keep the
efficacy of NSAIDS but with less serious side effects. The
new subfamily of NSAIDs, called CINODs, could be of interest
by limiting the NSAID-induced hypertension, a surrogate
marker for NSAID-induced myocardial infarction.  Clinical
studies are ongoing in order to confirm this positive effect.
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